27 reports of this reaction
3.0% of all ISOPROTERENOL HYDROCHLORIDE reports
#4 most reported adverse reaction
VENTRICULAR TACHYCARDIA is the #4 most commonly reported adverse reaction for ISOPROTERENOL HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 27 FDA adverse event reports linking ISOPROTERENOL HYDROCHLORIDE to VENTRICULAR TACHYCARDIA. This represents approximately 3.0% of all 894 adverse event reports for this drug.
Patients taking ISOPROTERENOL HYDROCHLORIDE who experience ventricular tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VENTRICULAR TACHYCARDIA is a less commonly reported adverse event for ISOPROTERENOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to ventricular tachycardia, the following adverse reactions have been reported for ISOPROTERENOL HYDROCHLORIDE:
The following drugs have also been linked to ventricular tachycardia in FDA adverse event reports:
VENTRICULAR TACHYCARDIA has been reported as an adverse event in 27 FDA reports for ISOPROTERENOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VENTRICULAR TACHYCARDIA accounts for approximately 3.0% of all adverse event reports for ISOPROTERENOL HYDROCHLORIDE, making it a notable side effect.
If you experience ventricular tachycardia while taking ISOPROTERENOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.